The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The global Drugs for Vulvovaginal Candidiasis market was valued at US$ 816.6 million in 2023 and is anticipated to reach US$ 907.4 million by 2030, witnessing a CAGR of 1.5% during the forecast period 2024-2030.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis.
Report Scope
The Drugs for Vulvovaginal Candidiasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030.
This report segments the global Drugs for Vulvovaginal Candidiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Vulvovaginal Candidiasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Bayer
- Perrigo
- J & J
- Pfizer
- Bristol-Myers Squibb
- Effik
- Teva
- Sanofi
- Cisen Pharmaceutical
- Kingyork Group
Segment by Type
- Cream
- Pessary
- Other
Segment by Application
- Hospital & Clinic
- Pharmacy
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs for Vulvovaginal Candidiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Drugs for Vulvovaginal Candidiasis Market Overview
1.1 Product Overview and Scope of Drugs for Vulvovaginal Candidiasis
1.2 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2024-2030)
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Value by Application: (2024-2030)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
1.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2019-2030
1.4.2 Global Drugs for Vulvovaginal Candidiasis Sales 2019-2030
1.4.3 Global Drugs for Vulvovaginal Candidiasis Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs for Vulvovaginal Candidiasis Market Competition by Manufacturers
2.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2019-2024)
2.4 Global Drugs for Vulvovaginal Candidiasis Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Type & Application
2.7 Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends
2.7.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue
2.7.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs for Vulvovaginal Candidiasis Retrospective Market Scenario by Region
3.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs for Vulvovaginal Candidiasis Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2019-2030
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2019-2024
3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2025-2030
3.3 Global Drugs for Vulvovaginal Candidiasis Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2019-2030
3.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2019-2024
3.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2025-2030
3.4 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.4.1 North America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2030)
3.4.3 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.5.1 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2030)
3.5.3 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2030)
3.6.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.7.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2030)
3.7.3 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2019-2030)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2019-2024)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2025-2030)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2019-2030)
4.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2019-2030)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2019-2024)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2025-2030)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2019-2030)
4.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2019-2030)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2019-2024)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2025-2030)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2019-2030)
5.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2019-2030)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2019-2024)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2025-2030)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2019-2030)
5.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Perrigo
6.2.1 Perrigo Corporation Information
6.2.2 Perrigo Description and Business Overview
6.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio
6.2.5 Perrigo Recent Developments/Updates
6.3 J & J
6.3.1 J & J Corporation Information
6.3.2 J & J Description and Business Overview
6.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio
6.3.5 J & J Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Effik
6.6.1 Effik Corporation Information
6.6.2 Effik Description and Business Overview
6.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio
6.6.5 Effik Recent Developments/Updates
6.7 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 Cisen Pharmaceutical
6.9.1 Cisen Pharmaceutical Corporation Information
6.9.2 Cisen Pharmaceutical Description and Business Overview
6.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio
6.9.5 Cisen Pharmaceutical Recent Developments/Updates
6.10 Kingyork Group
6.10.1 Kingyork Group Corporation Information
6.10.2 Kingyork Group Description and Business Overview
6.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio
6.10.5 Kingyork Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
7.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Vulvovaginal Candidiasis Production Mode & Process
7.4 Drugs for Vulvovaginal Candidiasis Sales and Marketing
7.4.1 Drugs for Vulvovaginal Candidiasis Sales Channels
7.4.2 Drugs for Vulvovaginal Candidiasis Distributors
7.5 Drugs for Vulvovaginal Candidiasis Customers
8 Drugs for Vulvovaginal Candidiasis Market Dynamics
8.1 Drugs for Vulvovaginal Candidiasis Industry Trends
8.2 Drugs for Vulvovaginal Candidiasis Market Drivers
8.3 Drugs for Vulvovaginal Candidiasis Market Challenges
8.4 Drugs for Vulvovaginal Candidiasis Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
